20 categories
Evidence
Published evidence, read closely. Trial digests, journal club, meta-analyses, preprints, and structured critique.
148 topics · page 4 of 5
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The…
|
+90 | 95 | 21k | 9mo |
|
Trial registration and comparing the protocol with the paper
Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…
|
+38 | 44 | 4.8k | 10mo |
|
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold?
The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. A question about…
|
+103 | 115 | 24k | 10mo |
|
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…
|
+11 | 15 | 4k | 10mo |
|
Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold?
The question in the title: Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold? I will give what I have already checked below so nobody repeats it. Asking about STEP 3 on…
|
2 | 15k | 10mo | |
|
Reverse causation in a cohort study of weight and outcome — a second dataset
Reverse causation in a cohort study of weight and outcome — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Reverse causation. It…
|
+112 | 131 | 1.5k | 10mo |
|
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
|
+80 | 91 | 10k | 11mo |
|
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. A preprint question rather than a question about the…
|
+148 | 160 | 31k | 11mo |
|
Coming back to: Sample size calculations, read backwards from the published number
On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Sample size calculations — I have the observation and I do not trust my…
|
+82 | 88 | 1.8k | 11mo |
|
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the…
|
+18 | 22 | 2.5k | 11mo |
|
Risk-of-bias tools and the judgement they conceal
Risk-of-bias tools and the judgement they conceal Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin risk-of-bias tools down and I want…
|
+8 | 12 | 21k | 11mo |
|
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. A methods question rather than a substantive one, about Criticising…
|
+16 | 20 | 61k | 11mo |
|
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
|
+21 | 25 | 21k | 11mo |
|
Immortal time bias in a claims-database study
Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. Asking about immortal time bias directly, because I have read four threads on it and each…
|
+29 | 34 | 28k | 11mo |
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…
|
+50 | 54 | 1.4k | 11mo |
|
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about what the numbers mean rather than what…
|
+105 | 118 | 18k | 11mo |
|
[2026 update] Heterogeneity as information rather than as a nuisance
Heterogeneity as information rather than as a nuisance Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
4 | 32k | 11mo | |
|
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
2 | 1.9k | 12mo | |
|
Comparators chosen for regulatory reasons rather than clinical ones — one year on
Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Comparators chosen for…
|
+82 | 87 | 1.1k | 12mo |
|
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting; the…
|
+2 | 6 | 39k | 12mo |
|
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on SURMOUNT-1. It is mine, it is…
|
+139 | 157 | 66k | 12mo |
|
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on CagriSema phase 2 combination paper.…
|
+74 | 79 | 2.3k | 13mo |
|
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Random versus fixed effects, and specifically the version of it that the…
|
+16 | 20 | 22k | 13mo |
|
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset
Posting this under the heading it deserves: Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Everything below is what sits behind that. Posting a small dataset on SURMOUNT-4 and…
|
+58 | 64 | 17k | 13mo |
|
Interim analyses and stopping rules — does this still hold?
Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Interim analyses and stopping rules, from the point of view…
|
+30 | 34 | 29k | 13mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
|
Second pass at: Trial registration and comparing the protocol with the paper
Posting this under the heading it deserves: Second pass at: Trial registration and comparing the protocol with the paper Everything below is what sits behind that. Two things I would like separated before…
|
+30 | 34 | 33k | 13mo |
|
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Something about individual participant data versus aggregate does not…
|
+30 | 34 | 64k | 14mo |
|
When a preprint is the best available evidence and we say so — a second dataset
When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. A preprint question rather than a…
|
+20 | 24 | 36k | 14mo |
|
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I would like to disagree carefully with the settled view on claim built, and I…
|
+71 | 80 | 1.1k | 14mo |